ERBB2 and breast carcinoma: ITK inhibitor ibrutinib inhibits luminal A breast cancer cells in vitro [149], represents safe treatment of solid tumors [150] and is currently being tested in a phase II clinical trial in Her2+ breast cancer patients (trial number: NCT03379428).